ASCO 2017

REVIEW UroToday

Viewing 1-20 of 183 articles

ASCO 2017: Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?

ASCO 2017: How Randomized Trials of STAMPEDE Have Influenced Treatment Decisions in the United Kingdom

ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer

ASCO 2017: Key Interdisciplinary and Integrated Treatment Planning Necessary to Effectively Treat Older Adults With Prostate Cancer

ASCO 2017: How Advances in Molecular Imaging Have Changed Our Understanding of State and Stage of the Disease

ASCO 2017: Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP)

ASCO 2017: Targeting the AR: Biomarkers and Novel Therapeutic Approaches

ASCO 2017: Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer?

ASCO 2017: Intensification of Therapy for Locally Advanced and Oligometastatic Disease (Discussing Abstract 5018, 5019, 5020)

ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer

ASCO 2017: PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration

ASCO 2017: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer

ASCO 2017: Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis

ASCO 2017: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial

ASCO 2017: Prostate cancer in 696 hypogonadal men with and without long-term testosterone therapy: Results from a controlled registry study

ASCO 2017: Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer

ASCO 2017: A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)

ASCO 2017: Avelumab in metastatic castration-resistant prostate cancer (mCRPC)

ASCO 2017: Assessment of quality of life, cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC)

ASCO 2017: Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer

1
2
3
4
5
6
7
8
9
10